Research gaps in pancreatic cancer research and comparative effectiveness research methodologies

Haejin In, Mitchell C. Posner

Research output: Contribution to journalArticle

Abstract

Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 % of patients are alive 5 years after diagnosis. Of the 10–20 % of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 % (Lim et al. in Annals of surgery 237(1):74–85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447–458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358–365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.

Original languageEnglish (US)
Pages (from-to)165-194
Number of pages30
JournalCancer Treatment and Research
Volume164
DOIs
StatePublished - 2015

Fingerprint

Comparative Effectiveness Research
Pancreatic Neoplasms
Research Design
Research
Disease Management
Adenocarcinoma
Survival Rate
Neoplasms
Therapeutics

Keywords

  • Adaptive clinical trials
  • Big data
  • Comparative effectiveness research
  • Databases
  • Expertise-based clinical trials
  • Pancreatic cancer research
  • Pancreatic cancer treatment
  • Tumor registries

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. / In, Haejin; Posner, Mitchell C.

In: Cancer Treatment and Research, Vol. 164, 2015, p. 165-194.

Research output: Contribution to journalArticle

@article{849500f004ef4aa08c17a8a2caba3782,
title = "Research gaps in pancreatic cancer research and comparative effectiveness research methodologies",
abstract = "Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 {\%} of patients are alive 5 years after diagnosis. Of the 10–20 {\%} of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 {\%} (Lim et al. in Annals of surgery 237(1):74–85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447–458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358–365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.",
keywords = "Adaptive clinical trials, Big data, Comparative effectiveness research, Databases, Expertise-based clinical trials, Pancreatic cancer research, Pancreatic cancer treatment, Tumor registries",
author = "Haejin In and Posner, {Mitchell C.}",
year = "2015",
doi = "10.1007/978-3-319-12553-4_10",
language = "English (US)",
volume = "164",
pages = "165--194",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Research gaps in pancreatic cancer research and comparative effectiveness research methodologies

AU - In, Haejin

AU - Posner, Mitchell C.

PY - 2015

Y1 - 2015

N2 - Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 % of patients are alive 5 years after diagnosis. Of the 10–20 % of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 % (Lim et al. in Annals of surgery 237(1):74–85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447–458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358–365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.

AB - Despite advances in cancer care, pancreatic adenocarcinoma remains one of the most lethal tumors. Most patients with pancreatic cancer are diagnosed with late stage disease, and approximately 6 % of patients are alive 5 years after diagnosis. Of the 10–20 % of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25 % (Lim et al. in Annals of surgery 237(1):74–85, 2003 [1]; Trede et al. in Annals of surgery 211(4):447–458, 1990 [2]; Crist et al. in Annals of surgery 206(3):358–365, 1987 [3]). Clearly, there is a need to improve the management of this disease. To identify gaps in research and formulate strategies to address these issues, we designed a framework to encompass the scope of research for pancreatic cancer. In this chapter, we will examine each topic heading within this framework for gaps in knowledge and present research strategies focusing on diverse comparative effectiveness research (CER) methodologies to address the identified gaps.

KW - Adaptive clinical trials

KW - Big data

KW - Comparative effectiveness research

KW - Databases

KW - Expertise-based clinical trials

KW - Pancreatic cancer research

KW - Pancreatic cancer treatment

KW - Tumor registries

UR - http://www.scopus.com/inward/record.url?scp=84923344019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923344019&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-12553-4_10

DO - 10.1007/978-3-319-12553-4_10

M3 - Article

VL - 164

SP - 165

EP - 194

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -